Low free plasma levels of retinol-binding protein 4 in insulin-insistant subjects with polycystic ovary syndrome

Journal of Endocrinological Investigation

Volumn 31, Issue 11, 2008, Pages 950-955

  Diamanti Kandarakis, E ^a   Livadas, S ^a   Kandarakis, S A ^b   Papassotiriou, I ^b   Margeli, A ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Insulin resistance; Petinol binding protein 4 (RBP4); Polycystic ovary syndrome (PCOS)

Indexed keywords

ANDROGEN; C REACTIVE PROTEIN; ESTRADIOL; GLUCOSE; GONADOTROPIN; INSULIN; PREALBUMIN; RETINOL BINDING PROTEIN 4;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ESTRADIOL BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEAN BODY WEIGHT; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PROTEIN BLOOD LEVEL;

EID: 59849087364     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345631     Document Type: Article

References (34)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999, 84: 4006-11.
2. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003, 52: 908-15.
3. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999, 28: 341-59.
4. Reaven GM, Hollenbeck CB, Chen YD. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 1989, 32: 52-5.
5. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006, 12: 324-32.
6. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436: 356-62.
7. Graham TE, Yang Q, Blüher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med 2006, 354: 2552-63.
8. Minokoshi Y, Kahn, RC, Kahn BB. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis. J Biol Chem 2003, 36: 33609-12.
9. Kim JK, Zisman A, Fillmore JJ, et al. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest 2001, 108: 153-60.
10. Broch M, Vendrell J, Ricart W, Richart C, Fernández-Real JM. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care 2007, 30: 1802-6.
11. Cho YM, Youn BS, Lee H, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006, 29: 2457-61.
12. Yao-Borengasser A, Varma V, Bodles AM, et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 2007, 92: 2590-7.
13. Tan BK, Chen J, Lehnert H, Kennedy R, Randeva HS. Raised serum, adipocyte, and adipose tissue retinol-binding protein 4 in overweight women with polycystic ovary syndrome: effects of gonadal and adrenal steroids. J Clin Endocrinol Metab 2007, 92: 2764-72.
14. Weiping L, Qingfeng C, Shikun M, et al. Elevated serum RBP4 is associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 2006, 30: 283-8.
15. Hahn S, Backhaus M, Broecker-Preuss M, et al. Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism. Eur J Endocrin 2007, 157: 201-7.
16. Janke J, Engeli S, Boschmann M, et al. Retinol-binding protein 4 in human obesity. Diabetes 2006, 55: 2805-10.
17. Monaco HL. The transthyretin-retinol binding protein complex. Biochim Biophys Acta 2000, 1482: 65-72.
18. Graham TE, Wason CJ, Blüher M, Kahn BB. Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia 2007, 50: 814-23.
19. Aeberli I, Biebinger R, Lehmann R, et al. Serum retinol-binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. J Clin Endocrinol Metab 2007, 92: 4359-65.
20. Raila J, Henze A, Spranger J, Möhlig M, Pfeiffer AF, Schweigert FJ. Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in type 2 diabetic patients. Kidney Int 2007, 72: 505-11.
21. National Institutes of Health Consensus Meeting on PCOS. In: Dunaif A, ed. Current issues in endocrinology and metabolism. Boston: Blackwell Scientific, 1992.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
23. Naylor HM, Newcomer ME. The structure of human retinal-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry 1999, 38: 2647-53.
24. Refai E, Dekki N, Yang SN, et al. Transthyretin constitutes a functional component in pancreatic-cell stimulus-secretion coupling. Proc Natl Acad Sci U S A 2005, 102: 17020-5.
25. Jia W, Wu H, Bao Y, et al. Association of serum retinol binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab 2007, Jun 5 [Epub ahead of print]; doi: 10.1210/jc.2007-0209.
26. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007, 92: 2712-9.
27. Silha JV, Nyomba BL, Leslie WD, Murphy LJ. Ethnicity, insulin resistance, and inflammatory adipokines in women at high and low risk for vascular disease. Diabetes Care 2007, 30: 286-91.
28. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89: 1273-6.
29. Schweigert FJ. Inflammation-induced changes in the nutritional biomarkers serum retinol and carotenoids. Curr Opin Clin Nutr Metab Care 2001, 4: 477-81.
30. Stephensen CB. Vitamin A, infection, and immune function. Annu Rev Nutr 2001, 21: 167-92.
31. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006, 21: 1426-31.
32. Vgontzas AN, Trakada G, Bixler EO, et al. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006, 55: 1076-82.
33. Lee JH, Chan L, Yiannakouris N, et al. Circulating resisting levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting leptin administration: cross-sectional and interventional study in normal, insulin-resistant and diabetic subjects. J Clin Endocrinol Metab 2003, 88: 4848-56.
34. Ukkola O. Resisting - a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinology 2002, 147: 571-4.